Register to view the archived recording here.
Q&A: NCI's Henry Rodriguez Says CPTC's Second Phase Will Focus on Applications
ProteoMonitor spoke to Henry Rodriguez, director of the Clinical Proteomic Technologies for Cancer program at NCI, about the recently announced reissuance of funds for the CPTC and what direction the initiative's research will take going forward.
New to GenomeWeb? Register here quickly.